PMID- 20127170
OWN - NLM
STAT- MEDLINE
DCOM- 20100616
LR  - 20211020
IS  - 1573-739X (Electronic)
IS  - 0928-1231 (Linking)
VI  - 32
IP  - 2
DP  - 2010 Apr
TI  - Haemophagocytic syndrome and paradoxical reaction to tuberculostatics after 
      treatment with infliximab.
PG  - 117-9
LID - 10.1007/s11096-010-9369-x [doi]
AB  - CASE: A 44-year-old man was diagnosed with ankylosing spondylitis, on treatment 
      with infliximab. After three doses, he was admitted to hospital with fever, 
      fatigue and nausea. A bone marrow biopsy confirmed haemophagocytic syndrome. He 
      was treated with immunoglobulin, cyclosporine and corticosteroids. CT scan 
      revealed tuberculosis. Tuberculostatic treatment was started 26 days after 
      admission. One month later, he was transferred intensive care with septic shock 
      and acute respiratory distress syndrome. After improvement, he was transferred to 
      the medical ward and later discharged. Two weeks after discharge, he was 
      readmitted with a suspected paradoxical reaction (PR) to tuberculostatics and 
      treated with prednisone. He was discharged 15 days later. CONCLUSIONS: In 
      patients treated with anti-TNF therapy it may be advisable to monitor the signs 
      and symptoms of tuberculosis. HPS is a rare complication of rheumatic diseases. 
      The possibility of developing a PR in immunosuppressed patients treated with 
      antituberculous should be considered.
FAU - Troncoso Marino, Amelia
AU  - Troncoso Marino A
AD  - Department of Pharmacy, Meixoeiro Hospital s/n, 36200, Vigo, Pontevedra, Spain. 
      ameliatroncoso@gmail.com
FAU - Campelo Sanchez, Eva
AU  - Campelo Sanchez E
FAU - Martinez Lopez de Castro, Noemi
AU  - Martinez Lopez de Castro N
FAU - Inaraja Bobo, Maria Teresa
AU  - Inaraja Bobo MT
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20100202
PL  - Germany
TA  - Pharm World Sci
JT  - Pharmacy world & science : PWS
JID - 9307352
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antitubercular Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - B72HH48FLU (Infliximab)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*adverse effects/therapeutic use
MH  - Antibodies, Monoclonal/*adverse effects/therapeutic use
MH  - Antitubercular Agents/*adverse effects/therapeutic use
MH  - Cyclosporine/therapeutic use
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/chemically induced
MH  - Immunocompromised Host
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infliximab
MH  - Lymphohistiocytosis, Hemophagocytic/*chemically induced
MH  - Male
MH  - Prednisone/therapeutic use
MH  - Spondylitis, Ankylosing/complications/*drug therapy
MH  - Tuberculosis, Pulmonary/complications/*drug therapy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2010/02/04 06:00
MHDA- 2010/06/17 06:00
CRDT- 2010/02/04 06:00
PHST- 2009/05/25 00:00 [received]
PHST- 2010/01/13 00:00 [accepted]
PHST- 2010/02/04 06:00 [entrez]
PHST- 2010/02/04 06:00 [pubmed]
PHST- 2010/06/17 06:00 [medline]
AID - 10.1007/s11096-010-9369-x [doi]
PST - ppublish
SO  - Pharm World Sci. 2010 Apr;32(2):117-9. doi: 10.1007/s11096-010-9369-x. Epub 2010 
      Feb 2.